These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32953229)

  • 1. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
    Levy D; Caballero T; Hussain I; Reshef A; Anderson J; Baker J; Schwartz LB; Cicardi M; Prusty S; Feuersenger H; Pragst I; Manning ME
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):136-141. PubMed ID: 32953229
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
    West JB; Poarch K; Lumry WR
    Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
    Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
    J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.
    Craig T; Feuersenger H; Pragst I; Dang J
    Allergy Asthma Proc; 2022 May; 43(3):202-208. PubMed ID: 35524357
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
    Levy DS; Farkas H; Riedl MA; Hsu FI; Brooks JP; Cicardi M; Feuersenger H; Pragst I; Reshef A
    Allergy Asthma Clin Immunol; 2020; 16():8. PubMed ID: 32042283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
    Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
    Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
    Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
    Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.
    Bernstein JA; Schwartz L; Yang W; Baker J; Anderson J; Farkas H; Aygören-Pürsün E; Bygum A; Jacobs I; Feuersenger H; Pragst I; Riedl MA
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):334-340.e1. PubMed ID: 32445670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema.
    Zuraw BL; Kalfus I
    Am J Med; 2012 Sep; 125(9):938.e1-7. PubMed ID: 22800873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
    Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
    Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
    Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
    Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency.
    Andrási N; Veszeli N; Holdonner Á; Temesszentandrási G; Kőhalmi KV; Varga L; Farkas H
    Int Immunopharmacol; 2020 Mar; 80():106216. PubMed ID: 31982824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
    Longhurst H; Cicardi M; Craig T; Bork K; Grattan C; Baker J; Li HH; Reshef A; Bonner J; Bernstein JA; Anderson J; Lumry WR; Farkas H; Katelaris CH; Sussman GL; Jacobs J; Riedl M; Manning ME; Hebert J; Keith PK; Kivity S; Neri S; Levy DS; Baeza ML; Nathan R; Schwartz LB; Caballero T; Yang W; Crisan I; Hernandez MD; Hussain I; Tarzi M; Ritchie B; Králíčková P; Guilarte M; Rehman SM; Banerji A; Gower RG; Bensen-Kennedy D; Edelman J; Feuersenger H; Lawo JP; Machnig T; Pawaskar D; Pragst I; Zuraw BL;
    N Engl J Med; 2017 Mar; 376(12):1131-1140. PubMed ID: 28328347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
    Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
    Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
    Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
    Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
    Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
    Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy.
    Tourangeau LM; Castaldo AJ; Davis DK; Koziol J; Christiansen SC; Zuraw BL
    Int Arch Allergy Immunol; 2012; 157(4):417-24. PubMed ID: 22123229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.